

# Registration is now open for RNA Therapeutics 2021

*SMi Group are delighted to announce their 12th annual conference RNA Therapeutics, taking place on 10th - 11th February 2021, London, UK.*

LONDON, KENSINGTON, UNITED KINGDOM, October 7, 2020 /EINPresswire.com/ -- The 2021 conference is set to explore the latest developments in [RNA](#) delivery agents and RNA-based [therapeutics](#) with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations.

NEW ADDITION TO THIS YEARS AGENDA!

The 2021 programme includes the new Focus Day on the 12th February which focuses on RNA Interference. Chaired by Shalini Andersson, Chief Scientist New Therapeutic Modalities & Head of Oligonucleotide Discovery, AstraZeneca.

Panel discussion on [COVID-19](#): how has the RNA industry adapted to beat the pandemic

Delegates stand to gain many valuable insights from this event such as:

- Industry insights into how mRNA is being used to combat COVID-19
- Case studies exploring the growing therapeutic potential of RNA for rare diseases
- Future trends in AI application for optimal RNA therapeutics
- A regulatory outlook of the RNA landscape, clinical trials and looking ahead

Visit the website for more details: [www.therapeutics-rna.com/einpr1](http://www.therapeutics-rna.com/einpr1)

CHAIR FOR 2021:



Heinrich Haas, VP RNA Formulation and Drug Delivery, BioNTech

Focus Day Chair for 2021: Shalini Andersson, Chief Scientist New Therapeutic Modalities & Head of Oligonucleotide Discovery, AstraZeneca

KEY SPEAKERS:

- Dong Yu, Fellow, Senior Director, and Head, GSK Vaccines
- Maria Luisa Pineda, CEO and Co-Founder, Envisagenics
- Kirsty Wydenbach, Deputy Unit Manager/Senior Medical Assessor, MHRA
- Dong Ki Lee, CEO, OliX
- Jennifer Pluim, Vice President Medical Affairs, ProQR
- Arpan Desai, Team Leader, Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca
- Ruchi Shah, Senior Research Engineer, New Therapeutics Modalities, Eli Lilly and Company
- Michael Mulqueen, Vice President Business Development, eTheRNA immunotherapies
- Troels Koch, Founder & CEO, Aqiventa

Further details about our speakers can be found here: [www.therapeutics-rna.com/einpr1](http://www.therapeutics-rna.com/einpr1)

Proudly sponsored by: Thermo Fisher Scientific

--- ENDS ---

Contact Information:

For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: [hsidhu@smi-online.co.uk](mailto:hsidhu@smi-online.co.uk)

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Jinna Sidhu  
SMi Group  
02078276088  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/527877886>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.